

Jeffrey R Idle

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/5335695/jeffrey-r-idle-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

141
papers

8,395
citations

53
h-index

88
g-index

144
ext. papers

9,065
ext. citations

6.4
avg, IF

5.75
L-index

#	Paper	IF	Citations
141	Plasma fetal bile acids 7 β -hydroxy-3-oxochol-4-en-24-oic acid and 3-oxachola-4,6-dien-24-oic acid indicate severity of liver cirrhosis. <i>Scientific Reports</i> , 2021 , 11, 8298	4.9	2
140	Metabolic Rewiring and the Characterization of Oncometabolites. <i>Cancers</i> , 2021 , 13,	6.6	8
139	Metabolomic and Lipidomic Biomarkers for Premalignant Liver Disease Diagnosis and Therapy. <i>Metabolites</i> , 2020 , 10,	5.6	21
138	(2,3)-Dihydroxybutanoic Acid Synthesis as a Novel Metabolic Function of Mutant Isocitrate Dehydrogenase 1 and 2 in Acute Myeloid Leukemia. <i>Cancers</i> , 2020 , 12,	6.6	3
137	Metabolomic insights into the mode of action of natural products in the treatment of liver disease. <i>Biochemical Pharmacology</i> , 2020 , 180, 114171	6	5
136	Mass isotopomer-guided decluttering of metabolomic data to visualize endogenous biomarkers of drug toxicity. <i>Biochemical Pharmacology</i> , 2018 , 156, 491-500	6	8
135	The plasma lipidome in acute myeloid leukemia at diagnosis in relation to clinical disease features. <i>BBA Clinical</i> , 2017 , 7, 105-114		23
134	Metabolomic Analysis of Mice Exposed to Gamma Radiation Reveals a Systemic Understanding of Total-Body Exposure. <i>Radiation Research</i> , 2017 , 187, 612-629	3.1	27
133	Robust Regression Analysis of GCMS Data Reveals Differential Rewiring of Metabolic Networks in Hepatitis B and C Patients. <i>Metabolites</i> , 2017 , 7,	5.6	9
132	Metabolic profiling by gas chromatography-mass spectrometry of energy metabolism in high-fat diet-fed obese mice. <i>PLoS ONE</i> , 2017 , 12, e0177953	3.7	38
131	A Novel Anti-Hepatitis C Virus and Antiproliferative Agent Alters Metabolic Networks in HepG2 and Hep3B Cells. <i>Metabolites</i> , 2017 , 7,	5.6	7
130	The metabolomic profile of gamma-irradiated human hepatoma and muscle cells reveals metabolic changes consistent with the Warburg effect. <i>PeerJ</i> , 2016 , 4, e1624	3.1	12
129	Disruption of tumor suppressor gene Hint1 leads to remodeling of the lipid metabolic phenotype of mouse liver. <i>Journal of Lipid Research</i> , 2014 , 55, 2309-19	6.3	6
128	A history and overview of phenotypic variability in CYP2D6 activity 2014 , 8-27		
127	Metabolic profiling of praziquantel enantiomers. <i>Biochemical Pharmacology</i> , 2014 , 90, 166-78	6	32
126	Noninvasive urinary metabolomic profiling identifies diagnostic and prognostic markers in lung cancer. <i>Cancer Research</i> , 2014 , 74, 3259-70	10.1	97
125	Metabolomics reveals trichloroacetate as a major contributor to trichloroethylene-induced metabolic alterations in mouse urine and serum. <i>Archives of Toxicology</i> , 2013 , 87, 1975-1987	5.8	21

124	Identification of 2-piperidone as a biomarker of CYP2E1 activity through metabolomic phenotyping. <i>Toxicological Sciences</i> , 2013 , 135, 37-47	4.4	12
123	The metabolomic window into hepatobiliary disease. <i>Journal of Hepatology</i> , 2013 , 59, 842-58	13.4	145
122	Tissue metabolomics of hepatocellular carcinoma: tumor energy metabolism and the role of transcriptomic classification. <i>Hepatology</i> , 2013 , 58, 229-38	11.2	141
121	Potential role of CYP2D6 in the central nervous system. <i>Xenobiotica</i> , 2013 , 43, 973-84	2	46
120	Metabolomics reveals aging-associated attenuation of noninvasive radiation biomarkers in mice: potential role of polyamine catabolism and incoherent DNA damage-repair. <i>Journal of Proteome Research</i> , 2013 , 12, 2269-81	5.6	27
119	Metabolomics and its potential in drug development. <i>Biochemical Pharmacology</i> , 2013 , 85, 12-20	6	50
118	Cytochrome P450 regulation by Etoposide in Pxr-null and PXR-humanized mice. <i>Drug Metabolism and Disposition</i> , 2013 , 41, 406-13	4	24
117	Dog bites man or man bites dog? The enigma of the amino acid conjugations. <i>Biochemical Pharmacology</i> , 2012 , 83, 1331-9	6	14
116	Metabolomics reveals the metabolic map of procainamide in humans and mice. <i>Biochemical Pharmacology</i> , 2012 , 83, 1435-44	6	31
115	The glycine deportation system and its pharmacological consequences. <i>Pharmacology & Therapeutics</i> , 2012 , 135, 151-67	13.9	39
114	Metabolomic markers for intestinal ischemia in a mouse model. <i>Journal of Surgical Research</i> , 2012 , 178, 879-87	2.5	20
113	Radiation metabolomics. 5. Identification of urinary biomarkers of ionizing radiation exposure in nonhuman primates by mass spectrometry-based metabolomics. <i>Radiation Research</i> , 2012 , 178, 328-40	3.1	76
112	Xenobiotic metabolomics: major impact on the metabolome. <i>Annual Review of Pharmacology and Toxicology</i> , 2012 , 52, 37-56	17.9	160
111	Novel metabolites and roles for Etoposide in humans and mice discovered by mass spectrometry-based metabolomics. <i>American Journal of Clinical Nutrition</i> , 2012 , 96, 818-30	7	44
110	Aberrant lipid metabolism in hepatocellular carcinoma revealed by plasma metabolomics and lipid profiling. <i>Cancer Research</i> , 2011 , 71, 6590-600	10.1	204
109	A comprehensive understanding of thioTEPA metabolism in the mouse using UPLC-ESI-QTOFMS-based metabolomics. <i>Biochemical Pharmacology</i> , 2011 , 81, 1043-53	6	27
108	The production and composition of rat sebum is unaffected by 3 Gy gamma radiation. <i>International Journal of Radiation Biology</i> , 2011 , 87, 360-71	2.9	11
107	Radiation metabolomics. 4. UPLC-ESI-QTOFMS-Based metabolomics for urinary biomarker discovery in gamma-irradiated rats. <i>Radiation Research</i> , 2011 , 175, 473-84	3.1	83

106	UPLC-MS-based urine metabolomics reveals indole-3-lactic acid and phenyllactic acid as conserved biomarkers for alcohol-induced liver disease in the Ppara-null mouse model. <i>Journal of Proteome Research</i> , 2011 , 10, 4120-33	5.6	59
105	Metabolomics reveals attenuation of the SLC6A20 kidney transporter in nonhuman primate and mouse models of type 2 diabetes mellitus. <i>Journal of Biological Chemistry</i> , 2011 , 286, 19511-22	5.4	59
104	Racemates revisited: heterochiral assemblies and the example of DL-thalidomide. <i>Xenobiotica</i> , 2011 , 41, 837-43	2	7
103	Analysis of N1-acetyl-N2-formyl-5-methoxykynuramine/N1-acetyl-5-methoxy-kynuramine formation from melatonin in mice. <i>Journal of Pineal Research</i> , 2010 , 49, 106-14	10.4	13
102	Urinary metabolomics in Fxr-null mice reveals activated adaptive metabolic pathways upon bile acid challenge. <i>Journal of Lipid Research</i> , 2010 , 51, 1063-74	6.3	36
101	Control of steroid 21-oic acid synthesis by peroxisome proliferator-activated receptor alpha and role of the hypothalamic-pituitary-adrenal axis. <i>Journal of Biological Chemistry</i> , 2010 , 285, 7670-85	5.4	18
100	Identification of noninvasive biomarkers for alcohol-induced liver disease using urinary metabolomics and the Ppara-null mouse. <i>Journal of Proteome Research</i> , 2010 , 9, 4176-88	5.6	53
99	The role of mass spectrometry-based metabolomics in medical countermeasures against radiation. <i>Mass Spectrometry Reviews</i> , 2010 , 29, 503-21	11	37
98	Xenobiotic metabolism: a view through the metabolometer. <i>Chemical Research in Toxicology</i> , 2010 , 23, 851-60	4	56
97	Comparative metabolism of cyclophosphamide and ifosfamide in the mouse using UPLC-ESI-QTOFMS-based metabolomics. <i>Biochemical Pharmacology</i> , 2010 , 80, 1063-74	6	45
96	Fenofibrate metabolism in the cynomolgus monkey using ultraperformance liquid chromatography-quadrupole time-of-flight mass spectrometry-based metabolomics. <i>Drug Metabolism and Disposition</i> , 2009 , 37, 1157-63	4	22
95	Rifampicin-activated human pregnane X receptor and CYP3A4 induction enhance acetaminophen-induced toxicity. <i>Drug Metabolism and Disposition</i> , 2009 , 37, 1611-21	4	98
94	Metabolomics reveals a novel vitamin E metabolite and attenuated vitamin E metabolism upon PXR activation. <i>Journal of Lipid Research</i> , 2009 , 50, 924-37	6.3	48
93	Serum metabolomics reveals irreversible inhibition of fatty acid beta-oxidation through the suppression of PPARalpha activation as a contributing mechanism of acetaminophen-induced hepatotoxicity. <i>Chemical Research in Toxicology</i> , 2009 , 22, 699-707	4	148
92	Radiation metabolomics. 3. Biomarker discovery in the urine of gamma-irradiated rats using a simplified metabolomics protocol of gas chromatography-mass spectrometry combined with random forests machine learning algorithm. <i>Radiation Research</i> , 2009 , 172, 198-212	3.1	85
91	Radiation metabolomics. 2. Dose- and time-dependent urinary excretion of deaminated purines and pyrimidines after sublethal gamma-radiation exposure in mice. <i>Radiation Research</i> , 2009 , 172, 42-57	3.1	95
90	Human urinary metabolomic profile of PPARalpha induced fatty acid beta-oxidation. <i>Journal of Proteome Research</i> , 2009 , 8, 4293-300	5.6	48
89	LC-MS-based metabolomics of acetaminophen-induced acute toxicity. <i>FASEB Journal</i> , 2009 , 23, 760.4	0.9	

88	Metabolomics reveals that hepatic stearyl-CoA desaturase 1 downregulation exacerbates inflammation and acute colitis. <i>Cell Metabolism</i> , 2008 , 7, 135-47	24.6	130
87	A metabolomic perspective of melatonin metabolism in the mouse. <i>Endocrinology</i> , 2008 , 149, 1869-79	4.8	50
86	UPLC-ESI-TOFMS-based metabolomics and gene expression dynamics inspector self-organizing metabolomic maps as tools for understanding the cellular response to ionizing radiation. <i>Analytical Chemistry</i> , 2008 , 80, 665-74	7.8	131
85	Identification of novel toxicity-associated metabolites by metabolomics and mass isotopomer analysis of acetaminophen metabolism in wild-type and Cyp2e1-null mice. <i>Journal of Biological Chemistry</i> , 2008 , 283, 4543-59	5.4	105
84	A double transgenic mouse model expressing human pregnane X receptor and cytochrome P450 3A4. <i>Drug Metabolism and Disposition</i> , 2008 , 36, 2506-12	4	48
83	Role of pregnane X receptor in control of all-trans retinoic acid (ATRA) metabolism and its potential contribution to ATRA resistance. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2008 , 324, 674-84	4.7	35
82	The pregnane X receptor: from bench to bedside. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2008 , 4, 895-908	5.5	89
81	Radiation metabolomics. 1. Identification of minimally invasive urine biomarkers for gamma-radiation exposure in mice. <i>Radiation Research</i> , 2008 , 170, 1-14	3.1	141
80	Pinning down the polo-box domain. <i>Chemistry and Biology</i> , 2008 , 15, 415-6		11
79	Rifaximin is a gut-specific human pregnane X receptor activator. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2007 , 322, 391-8	4.7	93
78	The metabolomics of (+/-)-arecoline 1-oxide in the mouse and its formation by human flavin-containing monooxygenases. <i>Biochemical Pharmacology</i> , 2007 , 73, 561-73	6	58
77	A comprehensive investigation of 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) metabolism in the mouse using a multivariate data analysis approach. <i>Chemical Research in Toxicology</i> , 2007 , 20, 531-42	4	57
76	Pharmacokinetics of tramadol is affected by MDR1 polymorphism C3435T. <i>European Journal of Clinical Pharmacology</i> , 2007 , 63, 419-21	2.8	23
75	Mouse lung CYP1A1 catalyzes the metabolic activation of 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP). <i>Carcinogenesis</i> , 2007 , 28, 732-7	4.6	24
74	The PREGnane X receptor gene-humanized mouse: a model for investigating drug-drug interactions mediated by cytochromes P450 3A. <i>Drug Metabolism and Disposition</i> , 2007 , 35, 194-200	4	116
73	Metabolomic and genetic analysis of biomarkers for peroxisome proliferator-activated receptor alpha expression and activation. <i>Molecular Endocrinology</i> , 2007 , 21, 2136-51		64
72	LC-MS-based metabolomics in drug metabolism. <i>Drug Metabolism Reviews</i> , 2007 , 39, 581-97	7	199
71	Metabolomics. <i>Cell Metabolism</i> , 2007 , 6, 348-51	24.6	126

70	The effect of pregnane X receptor (PXR)-mediated CYP3A induction on acetaminophen hepatotoxicity. <i>FASEB Journal</i> , 2007 , 21, A1184	0.9	
69	Role of the Pregnane X Receptor in the Clinical Resistance to all-trans Retinoic Acid. <i>FASEB Journal</i> , 2007 , 21, A1190	0.9	
68	CYP2D6 polymorphism, tramadol pharmacokinetics and pupillary response. <i>European Journal of Clinical Pharmacology</i> , 2006 , 62, 75-6; author reply 77-8	2.8	16
67	Comparative aromatic hydroxylation and N-demethylation of MPTP neurotoxin and its analogs, N-methylated beta-carboline and isoquinoline alkaloids, by human cytochrome P450 2D6. <i>Toxicology and Applied Pharmacology</i> , 2006 , 216, 387-98	4.6	37
66	3,4-Dehydrodebrisoquine, a novel debrisoquine metabolite formed from 4-hydroxydebrisoquine that affects the CYP2D6 metabolic ratio. <i>Drug Metabolism and Disposition</i> , 2006 , 34, 1563-74	4	12
65	Urinary metabolite profiling reveals CYP1A2-mediated metabolism of NSC686288 (aminoflavone). <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2006 , 318, 1330-42	4.7	56
64	Cerebral formation in situ of S-carboxymethylcysteine after ifosfamide administration to mice: a further clue to the mechanism of ifosfamide encephalopathy. <i>Toxicology Letters</i> , 2006 , 161, 188-94	4.4	11
63	A metabolomic approach to the metabolism of the areca nut alkaloids arecoline and arecaidine in the mouse. <i>Chemical Research in Toxicology</i> , 2006 , 19, 818-27	4	118
62	Urinary metabolites and antioxidant products of exogenous melatonin in the mouse. <i>Journal of Pineal Research</i> , 2006 , 40, 343-9	10.4	50
61	Differential metabolism of 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) in mice humanized for CYP1A1 and CYP1A2. <i>Chemical Research in Toxicology</i> , 2005 , 18, 1471-8	4	86
60	Metabolism of melatonin by human cytochromes p450. <i>Drug Metabolism and Disposition</i> , 2005 , 33, 489-94		224
59	Polymorphic cytochrome P450 2D6: humanized mouse model and endogenous substrates. <i>Drug Metabolism Reviews</i> , 2004 , 36, 243-77	7	102
58	The relative contribution of monoamine oxidase and cytochrome p450 isozymes to the metabolic deamination of the trace amine tryptamine. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2003 , 304, 539-46	4.7	47
57	Contribution of individual cytochrome P450 isozymes to the O-demethylation of the psychotropic beta-carboline alkaloids harmaline and harmine. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2003 , 305, 315-22	4.7	109
56	Screening for endogenous substrates reveals that CYP2D6 is a 5-methoxyindolethylamine O-demethylase. <i>Pharmacogenetics and Genomics</i> , 2003 , 13, 307-19		45
55	Regeneration of serotonin from 5-methoxytryptamine by polymorphic human CYP2D6. <i>Pharmacogenetics and Genomics</i> , 2003 , 13, 173-81		53
54	4-Hydroxylation of debrisoquine by human CYP1A1 and its inhibition by quinidine and quinine. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2002 , 301, 1025-32	4.7	40
53	The CYP2D6 humanized mouse: effect of the human CYP2D6 transgene and HNF4alpha on the disposition of debrisoquine in the mouse. <i>Molecular Pharmacology</i> , 2001 , 60, 1260-7	4.3	128

52	CYP2A6 polymorphism, nicotine, and environmental nitrosamines. <i>Lancet, The</i> , 1999 , 353, 2073	40	6
51	Genetic variation of CYP2A6, smoking, and risk of cancer. <i>Lancet, The</i> , 1999 , 353, 898-9	40	126
50	CYP2D6 phenotype-genotype relationships in African-Americans and Caucasians in Los Angeles. <i>Pharmacogenetics and Genomics</i> , 1998 , 8, 529-41		99
49	Characterization of the 16+9 kb and 30+9 kb CYP2D6 XbaI haplotypes. <i>Pharmacogenetics and Genomics</i> , 1997 , 7, 149-52		14
48	Lung cancer risk in relation to the CYP2C9 genetic polymorphism among Caucasians in Los Angeles County. <i>Pharmacogenetics and Genomics</i> , 1997 , 7, 401-4		30
47	Lack of correlation between phenotype and genotype for the polymorphically expressed dihydropyrimidine dehydrogenase in a family of Pakistani origin. <i>Pharmacogenetics and Genomics</i> , 1997 , 7, 161-3		31
46	CYP2D6 genotype and smoking behaviour in cigarette smokers. <i>Pharmacogenetics and Genomics</i> , 1997 , 7, 411-4		29
45	Antipsychotic drug-induced movement disorders in schizophrenics in relation to CYP2D6 genotype. <i>British Journal of Psychiatry</i> , 1997 , 170, 23-6	5.4	86
44	Ultrarapid metabolizers of debrisoquine: characterization and PCR-based detection of alleles with duplication of the CYP2D6 gene. <i>FEBS Letters</i> , 1996 , 392, 30-4	3.8	159
43	Lung cancer risk in relation to the CYP2C9*1/CYP2C9*2 genetic polymorphism among African-Americans and Caucasians in Los Angeles County, California. <i>Pharmacogenetics and Genomics</i> , 1996 , 6, 527-33		62
42	Lung cancer risk in relation to the CYP2E1 Rsa I genetic polymorphism among African-Americans and Caucasians in Los Angeles County. <i>Pharmacogenetics and Genomics</i> , 1996 , 6, 151-8		45
41	CYP2D6 genotypes in cigarette smokers and non-tobacco users. <i>Pharmacogenetics and Genomics</i> , 1996 , 6, 261-3		34
40	Nomenclature for human CYP2D6 alleles. <i>Pharmacogenetics and Genomics</i> , 1996 , 6, 193-201		348
39	Intrasubject variation in children of ifosfamide pharmacokinetics and metabolism during repeated administration. <i>Cancer Chemotherapy and Pharmacology</i> , 1996 , 38, 147-54	3.5	23
38	Polymorphism of glutathione S-transferase M1 and lung cancer risk among African-Americans and Caucasians in Los Angeles County, California. <i>Journal of the National Cancer Institute</i> , 1995 , 87, 1246-53	9.7	103
37	The kinetics of the auto-induction of ifosfamide metabolism during continuous infusion. <i>Cancer Chemotherapy and Pharmacology</i> , 1995 , 36, 53-60	3.5	49
36	Detection of the poor metabolizer-associated CYP2D6(D) gene deletion allele by long-PCR technology. <i>Pharmacogenetics and Genomics</i> , 1995 , 5, 215-23		230
35	Pharmacogenetics in the new patterns of healthcare delivery. <i>Pharmacogenetics and Genomics</i> , 1995 , 5, 347-50		8

34	Comparison of substrate metabolism by wild type CYP2D6 protein and a variant containing methionine, not valine, at position 374. <i>Pharmacogenetics and Genomics</i> , 1995 , 5, 234-43		32
33	S-mephenytoin hydroxylation phenotypes in a Jordanian population. <i>Clinical Pharmacology and Therapeutics</i> , 1995 , 58, 542-7	6.1	14
32	Identification of the major human hepatic cytochrome P450 involved in activation and N-dechloroethylation of ifosfamide. <i>Biochemical Pharmacology</i> , 1994 , 47, 1157-63	6	101
31	Reduced serum lipoprotein(a) levels in patients with primary biliary cirrhosis. <i>Atherosclerosis</i> , 1994 , 105, 43-50	3.1	34
30	Pharmacogenetic phenotyping and genotyping. Present status and future potential. <i>Clinical Pharmacokinetics</i> , 1994 , 26, 59-70	6.2	140
29	Genotyping of the CYP 2D6 gene in Norwegian lung cancer patients and controls. <i>Pharmacogenetics and Genomics</i> , 1994 , 4, 47-57		19
28	New Opportunities in Cancer Risk Evaluation Using PCR-Based DNA Analysis for CYP2D6. <i>Environmental Health Perspectives</i> , 1993 , 101, 117	8.4	1
27	Metabolic polymorphisms 1993 , 57, 129-60		159
26	Individual variation in the activation and inactivation of metabolic pathways of cyclophosphamide. <i>Journal of the National Cancer Institute</i> , 1992 , 84, 1744-8	9.7	32
25	Deficient nifedipine oxidation: a rare inherited trait associated with cystic fibrosis kindreds. <i>Pharmacogenetics and Genomics</i> , 1992 , 2, 19-24		16
24	The pharmacogenetics of chemical carcinogenesis. <i>Pharmacogenetics and Genomics</i> , 1992 , 2, 246-58		52
23	The role of individual human cytochromes P450 in drug metabolism and clinical response. <i>Trends in Pharmacological Sciences</i> , 1992 , 13, 434-9	13.2	202
22	Pharmacokinetics and metabolism of cyclophosphamide in paediatric patients. <i>Cancer Chemotherapy and Pharmacology</i> , 1992 , 30, 207-11	3.5	42
21	Comparison of a novel thin-layer chromatographic-fluorescence detection method with a spectrofluorometric method for the determination of 7-hydroxycoumarin in human urine. <i>Biomedical Applications</i> , 1992 , 575, 325-30		67
20	Combined thin-layer chromatography-photography-densitometry for the quantification of ifosfamide and its principal metabolites in urine, cerebrospinal fluid and plasma. <i>Biomedical Applications</i> , 1992 , 575, 137-42		20
19	Genetic and metabolic criteria for the assignment of debrisoquine 4-hydroxylation (cytochrome P4502D6) phenotypes. <i>Pharmacogenetics and Genomics</i> , 1991 , 1, 33-41		98
18	Is environmental carcinogenesis modulated by host polymorphism?. <i>Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis</i> , 1991 , 247, 259-66	3.3	65
17	Titrating exposure to tobacco smoke using cotinine--a minefield of misunderstandings. <i>Journal of Clinical Epidemiology</i> , 1990 , 43, 313-7	5.7	97

16	Combined thin-layer chromatography-photography-densitometry for the quantitation of cyclophosphamide and its four principal urinary metabolites. <i>Biomedical Applications</i> , 1988 , 427, 121-30		22
15	Trimethylaminuria (fish-odour syndrome) a study of an affected family. <i>Clinical Science</i> , 1988 , 74, 231-66.5		45
14	The relative importance of N-oxidation and N-demethylation in the metabolism of trimethylamine in man. <i>Toxicology</i> , 1987 , 43, 117-21	4.4	35
13	A genetic polymorphism of the N-oxidation of trimethylamine in humans. <i>Clinical Pharmacology and Therapeutics</i> , 1987 , 42, 588-94	6.1	95
12	Disclosure of the metabolic retroversion of trimethylamine N-oxide in humans: a pharmacogenetic approach. <i>Clinical Pharmacology and Therapeutics</i> , 1987 , 42, 608-12	6.1	46
11	Metabolic oxidation phenotypes as markers for susceptibility to lung cancer. <i>Nature</i> , 1984 , 312, 169-70	50.4	351
10	Prediction of subclinical perhexiline neuropathy in a patient with inborn error of debrisoquine hydroxylation. <i>American Heart Journal</i> , 1983 , 105, 159-61	4.9	11
9	Sex dimorphism of metiamide sulphoxidation and glucuronidation in rodent species. <i>Biochemical Society Transactions</i> , 1983 , 11, 183-184	5.1	
8	Elevated serum cholesterol in drug-oxidation-deficient rats. <i>Biochemical Pharmacology</i> , 1982 , 31, 1665-86		7
7	Spectral binding studies of the polymorphically metabolized drugs debrisoquine, sparteine and phenformin by cytochrome P-450 of normal and hydroxylation deficient rat strains. <i>Biochemical Pharmacology</i> , 1982 , 31, 3193-9	6	22
6	Taurine conjugates as metabolites of arylacetic acids in the ferret. <i>Xenobiotica</i> , 1978 , 8, 253-64	2	24
5	Glutamine conjugation of phenylacetic acid in the ferret [proceedings]. <i>Biochemical Society Transactions</i> , 1977 , 5, 1033-5	5.1	9
4	The conjugation of benzoic acid and phenylacetic acid by the Pipistrelle bat. <i>Comparative Biochemistry and Physiology Part C: Comparative Pharmacology</i> , 1977 , 58, 57-9		
3	Taurine conjugation of arylacetic acids in the ferret. <i>Biochemical Society Transactions</i> , 1976 , 4, 139-41	5.1	11
2	The conjugation of arylacetic acids in the pigeon compared with the hen. <i>Biochemical Society Transactions</i> , 1976 , 4, 141-43	5.1	6
1	A Metabolomic Perspective of Small Molecule Toxicity		2